The Hospital for Endocrine Surgery in Tampa, Florida, has opened a research institute for endocrine disease research and clinical trials.
The centre will focus primarily on thyroid cancer and was opened in collaboration with the Clayman Thyroid Center.
Its opening comes more than two years after the launch of the main hospital, which is dedicated to curative surgery for thyroid, parathyroid and adrenal gland tumours.
The new research institute is intended to become a central hub for research and trials, striving to enhance the understanding, diagnosis and treatment of thyroid cancer and other endocrine disorders.
A significant focus at the institute will be on cancer genetics, with plans to establish the world’s largest biobanking of thyroid cancers.
The resource is expected to allow oncologists to offer personalised cancer treatments based on individual genetics, potentially expediting the pace of research and transforming the care landscape for thyroid cancer patients worldwide.
Clayman Thyroid Center founder Dr Gary Clayman said: “We are excited to leverage our position as the highest-volume thyroid surgeons in the world to drive significant advancements in thyroid cancer research.
“With over 2,000 thyroid cancer operations performed annually, our unmatched patient volume uniquely positions us to expedite clinical trials, bringing cutting-edge treatments to patients more quickly and unlocking new insights into the biology and treatment of thyroid cancers.”
Surgeons from the Clayman Thyroid Center currently perform surgeries exclusively at the hospital in Tampa, working closely with surgeons from the Norman Parathyroid Center and the Carling Adrenal Center.
Hospital for Endocrine Surgery research institute lead Fabio Faucz said: “This Institute represents a significant step forward in our fight against thyroid cancer and other endocrine diseases.
“Our goal is to foster a collaborative environment where innovative ideas can flourish, and where our research can translate into tangible benefits for patients.”
